MMP-9 triggered self-assembly of doxorubicin nanofiber depots halts tumor growth

Biomaterials

Volumn 98, Issue , 2016, Pages 192-202

  Kalafatovic, Daniela ^a   Nobis, Max ^b   Son, Jiye ^a   Anderson, Kurt I ^b,d   Ulijn, Rein V ^a,c  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d THE FRANCIS CRICK INSTITUTE   (United Kingdom)

Author keywords

Cancer therapy; MMP; Morphology transition; Peptides; Self assembly

Indexed keywords

BIOMATERIALS; DISEASES; ENZYMES; PEPTIDES; TUMORS;

CANCER THERAPY; DISEASED TISSUES; ENDOGENOUS ENZYME; INHIBITION OF TUMOR GROWTH; MORPHOLOGY TRANSITIONS; OVER-EXPRESSION; POTENTIAL SITES; THERAPEUTIC COMPOUNDS;

SELF ASSEMBLY;

DOXORUBICIN; GELATINASE B; NANOFIBER; PEPTIDE; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CATALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MICELLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; ULTRASTRUCTURE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG CARRIERS; HUMANS; MATRIX METALLOPROTEINASE 9; MICE, NUDE; MICELLES; NANOFIBERS; NEOPLASM INVASIVENESS; NEOPLASMS; PEPTIDES;

EID: 84966713472     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.04.039     Document Type: Article

References (66)

1. Ventola C.L. The nanomedicine revolution: part 1: emerging concepts. Pharm. Ther. 2012, 37:512-525.
2. Bharali D.J., Mousa S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther. 2010, 128:324-335.
3. Da Silva C.G., Rueda F., Löwik C.W., Ossendorp F., Cruz L.J. Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials 2016, 83:308-320.
4. Schroeder A., et al. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 2011, 12:39-50.
5. Safra T., et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 2000, 1029-1033.
6. Patel J.D., et al. Clinical cancer advances 2013: annual report on progress against cancer from the American society of clinical oncology. J. Clin. Oncol. 2014, 32:129-160.
7. ® ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 2009, 4:99-105.
8. Wang X., Yang L., Chen Z.G., Shin D.M. Application of nanotechnology in cancer therapy and imaging. CA. Cancer J. Clin. 2008, 58:97-110.
9. Appel E.a, et al. Self-assembled hydrogels utilizing polymer-nanoparticle interactions. Nat. Commun. 2015, 6:1-9.
10. Smith D.J., et al. A multiphase transitioning peptide hydrogel for suturing ultrasmall vessels. Nat. Nanotechnol. 2015, 10.1038/nnano.2015.238.
11. Bhattacharyya J., et al. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models. Nat. Commun. 2015, 6:7939.
12. Newcomb C.J., et al. Cell death versus cell survival instructed by supramolecular cohesion of nanostructures. Nat. Commun. 2014, 5:3321.
13. Zhao L., et al. A review of polypeptide-based polymersomes. Biomaterials 2014, 35:1284-1301.
14. Zhang S. Fabrication of novel biomaterials through molecular self-assembly. Nat. Biotechnol. 2003, 21:1171-1178.
15. Zhang S., Zhao X., Spirio L. PuraMatrix: self-assembling peptide nanofiber scaffolds. Scaffolding Tissue Eng. 2005, 217-238.
16. Peng Z.-H., Kopecek J. Enhancing accumulation and penetration of HPMA copolymer doxorubicin conjugates in 2D and 3D prostate Cancer cells via iRGD conjugation with an MMP-2 cleavable spacer. J. Am. Chem. Soc. 2015, 137:6726-6729.
17. Barnard A., Smith D.K. Self-assembled multivalency: dynamic ligand arrays for high-affinity binding. Angew. Chem. Int. Ed. 2012, 51:6572-6581.
18. Li N., et al. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent. Biomaterials 2014, 35:9529-9545.
19. Hahn M.E., Gianneschi N.C. Enzyme-directed assembly and manipulation of organic nanomaterials. Chem. Commun. 2011, 47:11814.
20. Callmann C.E., et al. Therapeutic enzyme-responsive nanoparticles for targeted delivery and accumulation in tumors. Adv. Mater. 2015, 27:4611-4615.
21. Tanaka A., et al. Cancer cell death induced by the intracellular self-assembly of an enzyme-responsive supramolecular gelator. J. Am. Chem. Soc. 2015, 137:770-775.
22. Zhou J., Xu B. Enzyme-instructed self-assembly: a multi-step process for potential Cancer therapy. Bioconjug. Chem. 2015, 26:987-999.
23. Webber M.J., Newcomb C.J., Bitton R., Stupp S.I. Switching of self-assembly in a peptide nanostructure with a specific enzyme. Soft Matter 2011, 7:9665.
24. Zelzer M., Todd S.J., Hirst A.R., McDonald T.O., Ulijn R.V. Enzyme responsive materials: design strategies and future developments. Biomater. Sci. 2013, 1:11-39.
25. Noël A., Jost M., Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol. 2008, 19:52-60.
26. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
27. Yang Z., Ma M., Xu B. Using matrix metalloprotease-9 (MMP-9) to trigger supramolecular hydrogelation. Soft Matter 2009, 9:2546-2548.
28. Lutolf M.P., Raeber G.P., Zisch A.H., Tirelli N., Hubbell J.a Cell-responsive synthetic hydrogels. Adv. Mater. 2003, 15:888-892.
29. Vemula P.K., et al. On-demand drug delivery from self-assembled nanofibrous gels: a new approach for treatment of proteolytic disease. J. Biomed. Mater. Res. Part A 2011, 97A:103-110.
30. Gajanayake T., et al. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. Sci. Transl. Med. 2014, 6. 249ra110.
31. Lin Y.-A., Ou Y.-C., Cheetham A.G., Cui H. Rational design of MMP degradable peptide-based supramolecular filaments. Biomacromolecules 2014, 15:1419-1427.
32. Koda D., Maruyama T., Minakuchi N., Nakashima K., Goto M. Proteinase-mediated drastic morphological change of peptide-amphiphile to induce supramolecular hydrogelation. Chem. Commun. (Camb). 2010, 46:979-981.
33. Bremmer S.C., McNeil A.J., Soellner M.B. Enzyme-triggered gelation: targeting proteases with internal cleavage sites. Chem. Commun. 2014, 50:1691-1693.
34. Bacinello D., Garanger E., Taton D., Tam K.C., Lecommandoux S. Enzyme-degradable self-assembled nanostructures from polymer-peptide hybrids. Biomacromolecules 2014, 15:1882-1888.
35. Kuang Y., et al. Pericellular hydrogel/nanonets inhibit Cancer cells. Angew. Chem. Int. Ed. 2014, 53:8104-8107.
36. Pires R.a, et al. Controlling Cancer cell fate using localized biocatalytic self-assembly of an aromatic carbohydrate amphiphile. J. Am. Chem. Soc. 2015, 137:576-579.
37. Chien M.P., et al. Enzyme-directed assembly of a nanoparticle probe in tumor tissue. Adv. Mater. 2013, 25:3599-3604.
38. Li J., et al. Enzyme-Instructed intracellular molecular self-assembly to boost activity of cisplatin against drug-resistant Ovarian Cancer cells. Angew. Chem. 2015, 10.1002/ange.201507157.
39. Sanjana N.E., Shalem O., Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 2014, 11:006726.
40. Timpson P., et al. Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context. J. Vis. Exp. 2011, 56:e3089.
41. Tomayko M.M., Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989, 24:148-154.
42. Hennigan R.F., Hawker K.L., Ozanne B.W. Fos-transformation activates genes associated with invasion. Oncogene 1994, 9:3591-3600.
43. Kalafatovic D., et al. MMP-9 triggered micelle-to-fibre transitions for slow release of doxorubicin. Biomater. Sci. 2015, 3:246-249.
44. Rawlings N.D., Barrett A.J. MEROPS: the peptidase database. Nucleic Acids Res. 1999, 27:325-331.
45. Dilly A., et al. Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB. Int. J. Cancer 2013, 133:1784-1791.
46. Hahn M.E., Randolph L.M., Adamiak L., Thompson M.P., Gianneschi N.C. Polymerization of a peptide-based enzyme substrate. Chem. Commun. (Camb). 2013, 49:2873-2875.
47. Huang Y., Shi J., Yuan D., Zhou N., Xu B. Length-dependent proteolytic cleavage of short oligopeptides catalyzed by matrix metalloprotease-9. Biopolymers 2013, 100:790-795.
48. Hernandez-Guillamon M., et al. Sequential Abeta degradation by the matrix metalloproteases MMP-2 and MMP-9. J. Biol. Chem. 2015, 290:15078-15091.
49. Backstrom J.R., Lim G.P., Cullen M.J., Tökés Z.a Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci. 1996, 16:7910-7919.
50. Fleming S., et al. Assessing the utility of infrared spectroscopy as a structural diagnostic tool for β-sheets in self-assembling aromatic peptide amphiphiles. Langmuir 2013, 29:9510-9515.
51. Barth A., Zscherp C. What vibrations tell us about proteins. Q. Rev. Biophys. 2002, 35:369-430.
52. Kuang Y., Du X., Zhou J., Xu B. Supramolecular nanofibrils inhibit Cancer progression in vitro and in vivo. Adv. Healthc. Mater. 2014, 3:1217-1221.
53. Somiari S.B., et al. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int. J. Cancer 2006, 119:1403-1411.
54. Frankowski H., Gu Y., Heo J., Milner R., del Zoppo G. Use of gel zymography to examine matrix metalloproteinase (gelatinase) expression in brain tissue or in primary glial cultures. Astrocytes Methods Protoc. 2012, 814:221-233.
55. Björklund M., Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim. Biophys. Acta 2005, 1755:37-69.
56. Gao Y., Shi J., Yuan D., Xu B. Imaging enzyme-triggered self-assembly of small molecules inside live cells. Nat. Commun. 2012, 3:1033.
57. Gao Y., et al. Probing nanoscale self-assembly of nonfluorescent small molecules inside live mammalian cells. ACS Nano 2013, 7:9055-9063.
58. Jones J., Glynn P., Walker R. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J. Pathol. 1999, 168:161-168.
59. Richter M., et al. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin. Mol. Ther. Methods Clin. Dev. 2015, 10.1038/mtm.2015.5.
60. Yoo B., et al. Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast Cancer. Cancer Res. 2015, 75:4407-4415.
61. Morini M., et al. The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp-9) activity. Int. J. Cancer 2000, 87:336-342.
62. Balduyck M., et al. Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin. Exp. Metastasis 2000, 18:171-178.
63. Lee J., et al. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur. J. Cancer 2001, 37:106-113.
64. Hong B., Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics 2013, 3:377-394.
65. Naskar J., Palui G., Banerjee A. Tetrapeptide-based hydrogels: for encapsulation and slow release of an anticancer drug at physiological ph. J. Phys. Chem. B 2009, 113:11787-11792.
66. Zhang P., Cheetham A.G., Lin Y., Cui H. Self-assembled tat nano fibers as E ffective drug carrier and transporter. ACS Nano 2013, 7:5965-5977.